Author contributions: Funding acquisition: Podoltsev. Study concept: Podoltsev, Zhu, Zeidan, R. Wang, Ma. Formal analysis: Zhu. Methodology: R. Wang. Manuscript preparation: Podoltsev, Zhu, Ma. Manuscript review and editing: All authors.
Disclosures: Dr. Podoltsev has disclosed that he was a consultant for and received honoraria from Alexion and Pfizer, and received research support from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Celator, Pfizer, Astex Pharmaceuticals, CTI BioPharma, Celgene, Genentech, and LAM Therapeutics. Dr. Zhu has disclosed that she was a consultant for and received honoraria from AbbVie, Otsuka, Pfizer, Gilead, Celgene, Ariad, Incyte, Agios, Novartis, Takeda, Daiichi Sankyo, and Boehringer Ingelheim; was on the speakers bureau for Takeda; and received grant/research support from Celgene, Pfizer, Incyte, ADC Therapeutics, Medimmune, Takeda, AbbVie, and Boehringer Ingelheim. Dr. Davidoff has disclosed that she has received grant/research support from Celgene. Dr. Huntington has disclosed that he has received honoraria from Pharmacyclics and was a consultant for Celgene and Janssen. Dr. Gore has disclosed that he was consultant for and has received research support from Celgene. Dr. Ma has disclosed that she was a consultant for Celgene and Incyte and has received research support from Celgene. The remaining authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.
Disclaimer: The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the NCI’s SEER program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the CDC’s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the NCI, and the CDC or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services, Inc.; and the SEER Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors.
Srour SA, Devesa SS, Morton LM, et al.. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol 2016;174:382–396.
Tefferi A, Guglielmelli P, Larson DR, et al.. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507–2513, quiz 2615.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:94–108.
Hultcrantz M, Björkholm M, Dickman PW, et al.. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 2018;168:317–325.
Barbui T, Barosi G, Birgegard G, et al.. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761–770.
Mesa RA, Jamieson C, Bhatia R, et al.. NCCN Guidelines Insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw 2017;15:1193–1207.
Barbui T, Tefferi A, Vannucchi AM, et al.. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018;32:1057–1069.
Mascarenhas J, Mesa R, Prchal J, et al.. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica 2014;99:945–949.
Cortelazzo S, Finazzi G, Ruggeri M, et al.. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132–1136.
Harrison CN, Campbell PJ, Buck G, et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45.
Gisslinger H, Gotic M, Holowiecki J, et al.. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013;121:1720–1728
Warren JL, Klabunde CN, Schrag D, et al.. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-3–18.
Zuo J, Curtis LM, Yao X, et al.. Glucocorticoid receptor expression in the postnatal rat cochlea. Hear Res 1995;87:220–227.
Price GL, Davis KL, Karve S, et al.. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014;9:e90299.
Kind S, Virnig B, McBean AM. SEER-Medicare: Defining the Date of Diagnosis & Treatment. Available at: https://healthcaredelivery.cancer.gov/seermedicare/considerations/date.html. Accessed September 14, 2018.
Hollenbeck BK, Ye Z, Dunn RL, et al.. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009;101:571–580.
Healy MA, Yin HY, Reddy RM, Wong SL. Use of positron emission tomography to detect recurrence and associations with survival in patients with lung and esophageal cancers. J Natl Cancer Inst 2016;108:djv429.
Raebel MA, Schmittdiel J, Karter AJ, et al.. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013;51(8 Suppl 3):S11–21.
Gupta A, Long JB, Chen J, et al.. Risk of vascular toxicity with platinum based chemotherapy in elderly patients with bladder cancer. J Urol 2016;195:33–40.
Davidoff AJ, Zuckerman IH, Pandya N, et al.. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol 2013;4:157–165.
Klabunde CN, Potosky AL, Legler JM, et al.. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
Previtali E, Bucciarelli P, Passamonti SM, et al.. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120–138.
Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology Am Soc Hematol Educ Program 2017;2017:480–488.
Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al.. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015;5:e369.